11:40 AM EDT, 08/06/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our target price to USD40 from USD34, which implies 20x our 2025 EPADS estimate. This is broadly in line with the comparable peer average but above its 3-year historical forward P/E of 15.3x, justified in our view by the anticipated recovery from the realization of the 12-Point Plan. We keep our EPADS estimates of USD2.00 for 2025 and USD2.12 for 2026. Considering its large U.S. manufacturing base (54% of revenue is from the U.S., of which two-thirds is manufactured domestically), we view the company as relatively better equipped to navigate the potential impact of tariffs. We expect growth to be supported by new product launches and productivity improvements from its 12-Point Plan, which is progressing well. We are encouraged by the return to growth in U.S. Hip Implants in Q2 2024 and U.S. Knee Implants in Q3 2024 (as previously progress was slower than expected), with further improvements seen in the H1 2025.